Results 51 to 55 of about 909 (55)

Defining clinical endpoints in limb girdle muscular dystrophy: a GRASP-LGMD study. [PDF]

BMC Neurol
Doody A, Alfano L, Diaz-Manera J, Lowes L, Mozaffar T, Mathews KD, Weihl CC, Wicklund M, Hung M, Statland J, Johnson NE, GRASP-LGMD Consortium.   +11 more
europepmc   +1 more source

Recombinant protein expression in <i>Acanthamoeba castellanii</i>. [PDF]

Front Bioeng Biotechnol
Salunke P, Kondabagil K, Karpe YA.
europepmc   +1 more source

NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion. [PDF]

Mol Cancer Res
Noronha KJ, Lucas KN, Paradkar S, Edmonds J, Friedman S, Murray MA, Liu S, Sajed DP, Sachs C, Spurrier J, Raponi M, Liang J, Zeng H, Sundaram RK, Shuch B, Vasquez JC, Bindra RS.   +16 more
europepmc   +1 more source

C1'-Branched Acyclic Nucleoside Phosphonates as Inhibitors of Plasmodium Falciparum 6-Oxopurine Phosphoribosyltransferase. [PDF]

ChemMedChem
Frydrych J, Keough DT, Xia H, Slavětínská LP, Dračínský M, Česnek M, Travis J, Chavchich M, Edstein M, Hocková D, Guddat LW, Janeba Z.   +11 more
europepmc   +1 more source

Degradation of [3H]thymidine by a pentosyltransferase (EC 2.4.2.4) in the plasma of man and different animals

Experientia, 1977
[3H]Thymidine is degraded by an enzyme (thymidine phosphorylase; EC 2.4.2.4) which we have identified in the plasma of man and some animals. The presence of this enzyme in plasma or sera used to supplement culture media may, under certain experimental conditions, limit the validity of measuring the uptake of radiolabeled thymidine as a means of ...
J L, Pauly, M G, Schuller, A A, Zelcer, M J, Germain   +3 more
openaire   +2 more sources